Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas Aeruginosa Isolated from Patients of Lower Respiratory Tract Infections

Overview

Journal Springerplus

Date 2013 Feb 12

PMID 23397507

Citations 10

Authors

Anab Fatima

Syed Baqir Naqvi

Sheikh Abdul Khaliq

Shaheen Perveen

Sabahat Jabeen

Affiliations

Soon will be listed here.

Abstract

The present study was conducted to determine the antibiotic susceptibility pattern of Pseudomonas aeruginosa from sputum samples of lower respiratory tract infection patients admitted to different hospitals of Karachi. Most of the hospitals are hampered with high frequency of nosocomial infections generally caused by multiresistant nosocomial pathogen. Among Gram-negative pathogens Pseudomonas aeruginosa considered as most challenging pathogen. The objective of the study was to determine frequency of Pseudomonas aeruginosa from sputum samples and to find out susceptibility pattern against four antibiotics widely used for treatment. The sputum samples from 498 patients were collected consecutively between January 2010 and March 2011 and were cultured and identified. According to CLSI (Clinical Laboratory Standards Institute) guidelines antimicrobial susceptibility testing was performed by disc diffusion method. Pseudomonas aeruginosa were isolated from 24% (120/498) of the lower respiratory tract patient. A higher resistance to Pseudomonas aeruginosa isolate was observed with piperacillin/tazobactam and cefipime i.e. 42% and 40% respectively. Imipenem was found to be most effective antibiotic against Pseudomonas aeruginosa (76% sensitivity) but amikacin resistance was continuously increasing. In conclusion the frequency of Pseudomonas aeruginosa was also higher among lower respiratory tract infection patients with alarmingly high rate of resistance among widely used antibiotics. These findings focused on careful consideration for monitoring and optimization of antimicrobial use in order to reduce occurrence and spread of antimicrobial resistant pathogen.

Citing Articles

Antimicrobial resistance and carbapenemase dissemination in isolates from Libyan hospitals: a call for surveillance and intervention.

Gadaime N, Haddadin R, Shehabi A, Omran I Libyan J Med. 2024; 19(1):2344320.

PMID: 38643488 PMC: 11034451. DOI: 10.1080/19932820.2024.2344320.

Estimation, Evaluation and Characterization of Carbapenem Resistance Burden from a Tertiary Care Hospital, Pakistan.

Gondal A, Choudhry N, Bukhari H, Rizvi Z, Jahan S, Yasmin N Antibiotics (Basel). 2023; 12(3).

PMID: 36978392 PMC: 10044297. DOI: 10.3390/antibiotics12030525.

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia.

Alsaleh N, Al-Omar H, Mayet A, Mullen A Saudi Pharm J. 2020; 28(11):1492-1498.

PMID: 33250656 PMC: 7679439. DOI: 10.1016/j.jsps.2020.09.015.

Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal.

Yadav S, Bhujel R, Mishra S, Sharma S, Sherchand J BMC Res Notes. 2020; 13(1):319.

PMID: 32616058 PMC: 7330544. DOI: 10.1186/s13104-020-05163-6.

Five-Year Antimicrobial Susceptibility of Pseudomonas aeruginosa from a Local Tertiary Hospital in Bacolod City, Philippines.

Juayang A, Lim J, Bonifacio A, Lambot A, Millan S, Sevilla V Trop Med Infect Dis. 2018; 2(3).

PMID: 30270886 PMC: 6082103. DOI: 10.3390/tropicalmed2030028.

References

Akhtar N . Hospital acquired infections in a medical intensive care unit. J Coll Physicians Surg Pak. 2010; 20(6):386-90. DOI: 06.2010/JCPSP.386390. View

Carmeli Y, Troillet N, Eliopoulos G, Samore M . Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999; 43(6):1379-82. PMC: 89282. DOI: 10.1128/AAC.43.6.1379. View

Agarwal R, Gupta D, Ray P, Aggarwal A, Jindal S . Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in North India. J Infect. 2005; 53(2):98-105. DOI: 10.1016/j.jinf.2005.10.021. View

Trilla A . Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med. 1994; 20 Suppl 3:S1-4. DOI: 10.1007/BF01745243. View

Sader H, Jones R, Gales A, Winokur P, Kugler K, Pfaller M . Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study.... Diagn Microbiol Infect Dis. 1999; 32(4):289-301. DOI: 10.1016/s0732-8893(98)00124-2. View

Jarlier V, Fosse T, Philippon A . Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med. 1996; 22(10):1057-65. DOI: 10.1007/BF01699228. View

Friedland I, Funk E, Khoosal M, Klugman K . Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother. 1992; 36(8):1596-600. PMC: 192005. DOI: 10.1128/AAC.36.8.1596. View

Balkhy H, Cunningham G, Chew F, Francis C, Al Nakhli D, Almuneef M . Hospital- and community-acquired infections: a point prevalence and risk factors survey in a tertiary care center in Saudi Arabia. Int J Infect Dis. 2006; 10(4):326-33. DOI: 10.1016/j.ijid.2005.06.013. View

Jarvis W, Martone W . Predominant pathogens in hospital infections. J Antimicrob Chemother. 1992; 29 Suppl A:19-24. DOI: 10.1093/jac/29.suppl_a.19. View

10.

Gerding D, Larson T, Hughes R, Weiler M, Shanholtzer C, Peterson L . Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 1991; 35(7):1284-90. PMC: 245159. DOI: 10.1128/AAC.35.7.1284. View

11.

Rotimi V, Al-Sweih N, Feteih J . The prevalence and antibiotic susceptibility pattern of gram-negative bacterial isolates in two ICUs in Saudi Arabia and Kuwait. Diagn Microbiol Infect Dis. 1998; 30(1):53-9. DOI: 10.1016/s0732-8893(97)00180-6. View

12.

Bonfiglio G, Carciotto V, Russo G, Stefani S, Schito G, Debbia E . Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother. 1998; 41(2):307-10. DOI: 10.1093/jac/41.2.307. View

13.

Quinn J . Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis. 1998; 27 Suppl 1:S117-24. DOI: 10.1086/514912. View

14.

Hancock R . Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998; 27 Suppl 1:S93-9. DOI: 10.1086/514909. View

15.

Lizioli A, Privitera G, Alliata E, Antonietta Banfi E, Boselli L, Panceri M . Prevalence of nosocomial infections in Italy: result from the Lombardy survey in 2000. J Hosp Infect. 2003; 54(2):141-8. DOI: 10.1016/s0195-6701(03)00078-1. View

16.

MacFarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V . Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001; 56(2):109-14. PMC: 1746009. DOI: 10.1136/thorax.56.2.109. View

17.

Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz M . Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother. 1999; 43(4):981-2. PMC: 89243. DOI: 10.1128/AAC.43.4.981. View

18.

Srifuengfung S, Tiensasitorn C, Yungyuen T, Dhiraputra C . Prevalence and antimicrobial susceptibility of Pseudomonas aeruginosa mucoid and non-mucoid type. Southeast Asian J Trop Med Public Health. 2005; 35(4):893-6. View

19.

Erasmo A, Crisostomo A, Yan L, Hong Y, Lee K, Lo C . Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg. 2004; 27(3):227-35. DOI: 10.1016/S1015-9584(09)60039-7. View

20.

Bustamante C, Drusano G, Wharton R, Wade J . Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother. 1987; 31(4):632-4. PMC: 174794. DOI: 10.1128/AAC.31.4.632. View